Reference Library

This document provides an overview of the essential elements and best practices for site close-out and handling outstanding queries and discrepancies prior to trial completion.

The ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, and Complete) outline standards for data management and integrity in clinical research. These principles are crucial for ensuring that clinical data is credible and valid.

These guidelines provide a comprehensive framework for monitoring clinical trials, ensuring that they are conducted according to ethical and scientific standards. They underscore the importance of maintaining oversight throughout the trial process.

Although primarily focused on laboratory practices, this ICH guideline emphasizes the importance of data accuracy and protocol adherence, which are relevant to all aspects of clinical trials, including conduct and monitoring.

This ICH guideline outlines the principles of Good Clinical Practice, including the requirements for informed consent and monitoring of clinical trials. It is essential for ensuring the rights, safety, and well-being of trial participants.

This ICH guideline provides recommendations for the management of clinical safety data, including serious adverse events (SAEs) and suspected unexpected serious adverse reactions (SUSARs). Understanding these requirements is critical for compliance and participant safety.

This guideline focuses on the reporting and management of adverse drug reactions and other safety data in clinical trials. It emphasizes the importance of timely reporting of SAEs and the overall monitoring of participant safety.

The current international GCP guideline (supersedes R2, finalised 2023) covering ethics, study conduct, investigator responsibilities, data integrity, risk-based monitoring, and documentation standards for clinical trials.

Provides guidance on the structure and content of clinical study reports for submission to regulatory authorities.

This guideline provides a framework for the ethical and scientific quality of clinical trials, emphasizing the importance of protocol design, data integrity, and participant safety. It is essential for professionals to understand these principles to ensure compliance and enhance trial quality.

This guideline outlines general principles for designing and conducting clinical trials, focusing on the importance of scientific quality and ethical considerations. It provides valuable insights into study concept development and protocol structuring.

This guideline outlines the principles of Good Clinical Practice (GCP) applicable to the design, conduct, recording, and reporting of clinical trials. Section 8 specifically addresses the responsibilities related to archiving essential documents, which is crucial during the close-out phase of a trial.

This integrated addendum emphasizes risk-based approaches to monitoring, including programmatic considerations for data integrity and quality during the close-out phase of clinical trials.

This guideline provides a framework for designing, conducting, overseeing, and reporting clinical trials. It emphasizes the importance of ensuring ethical and scientific quality in the design and reporting of clinical studies.

ICH E3 outlines the structure and content necessary for Clinical Study Reports (CSRs). It ensures consistency and quality in reporting clinical trial results, central to regulatory submissions.

This guideline provides principles and approaches for statistical analyses in clinical trials. It aids in the design and analysis, ensuring findings are valid and reliable.

This addendum describes the concept of estimands, enhancing clarity in the definition and analysis of treatment effects. It is crucial for developing robust statistical plans.

This regulation lays down a framework for conducting clinical trials in the EU, focusing on the protection of study participants and the integrity of trial data. It is crucial for planning and executing clinical trials effectively within European jurisdictions.

This regulation specifies the requirements for informed consent in clinical trials conducted in the United States. Compliance with these regulations is critical for ethical research practices and participant safety.

This manual provides detailed procedures for FDA investigational compliance, including aspects related to close-out activities, such as documentation review and sponsor obligations at the end of a trial.

US federal regulations governing the submission of Investigational New Drug applications and the conduct of clinical investigations.

This technical guide outlines the standards for the submission of clinical study data. CDISC standards facilitate data submission and promote interoperability in clinical research.

This document provides standards for data submission formats, including the Clinical Data Acquisition Standards Harmonization (CDASH) for the collection of clinical trial data. It emphasizes the need for proper data validation and reconciliation prior to database lock.

This guidance provides principles for conducting blind review meetings during clinical trial oversight. Proper execution of these meetings ensures unbiased evaluation of trial data.

This draft guidance discusses the requirements for handling protocol deviations and underscores the impact of these deviations on the integrity of clinical trials and data quality.

This document examines the foundations of informed consent in clinical research, detailing the ethical and regulatory requirements that must be met before enrolling participants. Understanding these requirements is essential for ensuring participant rights and ethical conduct.

This guidance discusses the significance of data integrity in clinical trials, particularly at the time of close-out, emphasizing the importance of accurate data capture and resolution of discrepancies.

This guidance document details the requirements and best practices for preparing and submitting a Clinical Study Report to regulatory authorities. Adhering to these guidelines is critical for regulatory approvals.

This guidance provides a comprehensive overview of the necessary content and format for IND applications. It emphasizes the importance of clear protocol design and adequate safety information for regulators to evaluate the proposed clinical trial.

This guidance provides key principles of Good Clinical Practice (GCP) to be incorporated into protocol design. It aids researchers in developing effective study protocols that comply with regulatory standards and scientific integrity.

This guidance document provides detailed information on the IND application process, including required elements, and serves as a critical resource for researchers preparing to conduct clinical trials in the US. It emphasizes the importance of complete protocol design and regulatory compliance.

This FDA guidance outlines the requirements for submitting clinical study data as part of the new drug application process. It highlights the importance of data quality and integrity in submissions.

This guidance focuses on leveraging electronic health records (EHR) for clinical trial data collection, emphasizing the importance of data reconciliation and proper procedures during the close-out process.

This guidance outlines considerations for the capture and use of electronic source data in clinical investigations, including requirements for data integrity, query resolution, and data reconciliation, which are pivotal at the close-out phase.

This foundational document describes the PICO (Population, Intervention, Comparison, Outcome) framework for formulating research questions. It is essential for structuring study aims and enhancing the clarity of clinical trial protocols.

FDA guidance on the principles of data integrity in GxP-regulated environments, emphasizing attributable, legible, contemporaneous, original, and accurate records.